- Product Details
- Description
- Additional information
- More Offers
Description
Background Information:
A potent, selective and orally active inhibitor of VEGFRs 1, 2 and 3, currently in clinical trial.
Reference:
1. Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 2008 Mar;99(3):623-30.
2. Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66(18):9134-42.
3. Murakami M, Iwai S, Hiratsuka S, Yamauchi M, Nakamura K, Iwakura Y, Shibuya M. Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood. 2006 Sep 15;108(6):1849-56.
APIM050010: AV-951 (TIVOZANIB)
CAS No.: 475108-18-0.
Molecular Formula: C22H19ClN4O5.
Molecular Weight: 454.85.
Purity: 99% (HPLC).
QC: LC/MS, 1HNMR.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Additional information
| Ship from Country | USA |
|---|---|
| Size | 10 mg, 100 mg, 50 mg |
